VM-26 in colorectal carcinoma: a Southwest Oncology Group study.
In this multi-institutional phase II study, VM-26 or Teniposide was administered to forty-two patients with advanced colorectal cancer. Patients were initially treated at 60 mg/M2 daily for 5 days with dose adjustments depending on toxicity. One complete response and one partial response were observed lasting six and four months respectively. Leukopenia was severe in 40% of patients. No drug related deaths were seen. In this Southwest Oncology Group (SWOG) study, VM-26 appeared to have minimal benefit in advanced colorectal cancer.
Cancer Research Center of Hawaii.
N
N
Oishi
T R
TR
Fleming
L
L
Laufman
J S
JS
Ungerleider
R B
RB
Natale
A B
AB
Einstein
D D
DD
Von Hoff
J S
JS
Macdonald
D015179:Colorectal Neoplasms / Q000188:drug therapy*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D015337:Multicenter Studies as Topic; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D013713:Teniposide / Q000009:adverse effects / Q000627:therapeutic use*
D013713:Teniposide; D011034:Podophyllotoxin